Drugs / Diphenhydramine
Diphenhydramine
also known as
Benadryl · Diphenhydramine Hydrochloride · Diphenhydramine HCl · DPH · Diphenydramine · Benadryl demand · DHP HCL · Diphenhydramin · +5 more
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | BENADRYL | — | 1984-08-30 | fda.gov ↗ |
| Approved | US (FDA) | BENADRYL | — | 1946-03-04 | fda.gov ↗ |
Trials 57 · a red edge is where a trial was stopped
1944194519461947194819491950195119521953195419551956195719581959196019611962196319641965196619671968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028202920302031203220332034
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02142543 | Mar → Dec 2012 | aphthous stomatitis | Texas A&M University | Completed | No outcome recorded |
| Phase 110 trials | ||||||
| Phase 1 | NCT04741139 | Sep 2021 → Dec 2022 | autoimmune thrombocytopenia | Baylor College of Medicine | Unknown | No outcome recorded |
| Phase 1 | NCT04093271 | Sep → Dec 2019 | — | LifeSeasons Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03424135 | Mar → Apr 2018 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT03396250 | Feb → Mar 2018 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT02476058 | Jun 2015 → Jan 2016 | major depressive disorder | Janssen-Cilag International NV | Completed | No outcome recorded |
| Phase 1 | NCT01965301 | Oct 2014 | — | Bioprojet | Terminated | No outcome recorded |
| Phase 1 | NCT01737931 | Aug → Oct 2012 | — | Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT00762749 | Sep → Nov 2008 | allergic rhinitis | Johnson & Johnson Consumer and Personal Products Worldwide | Completed | No outcome recorded |
| Phase 1 | NCT00240123 | Jul 2005 → Jul 2007 | gallbladder disorder, gallstones, hyperbilirubinemia, pancreatitis | University of Rochester | Withdrawn | No outcome recorded |
| Phase 1 | NCT00223691 | Mar 2002 → Jan 2017 | autonomic nervous system disorder, orthostatic hypotension | Vanderbilt University | Completed | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT07358689 | Jun 2026 → Jan 2028 expected | non-small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05501678 | Aug 2023 → Dec 2027 expected | autism | Stanford University | Recruiting | No outcome recorded |
| Phase 2 | NCT04846348 | Jul → Sep 2021 | cutaneous mastocytosis | Joseph Butterfield | Terminated | No outcome recorded |
| Phase 2 | NCT02671760 | Feb → Jun 2016 | insomnia | Sequential Medicine Ltd | Completed | No outcome recorded |
| Phase 2 | NCT02142712 | Dec 2014 | brain edema, stroke disorder | University of Florida | Completed | No outcome recorded |
| Phase 2 | NCT00837941 | Apr → Aug 2009 | diabetic polyneuropathy | Merck Sharp & Dohme LLC | Withdrawn | No outcome recorded |
| Phase 2 | NCT00429702 | Oct 2007 → Aug 2009 | childhood malignant neoplasm | University of South Florida | Terminated | No outcome recorded |
| Phase 2 | NCT00590590 | Oct 2007 → Jun 2009 | vulvodynia | Lumara Health, Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06702670 | Mar 2025 → Mar 2027 expected | dystocia | The University of Texas Health Science Center, Houston | Recruiting | No outcome recorded |
| Phase 314 trials | ||||||
| Phase 3 | NCT06910241 | Sep 2025 → Jun 2027 expected | — | Florida Atlantic University | Recruiting | No outcome recorded |
| Phase 3 | NCT06704620 | Dec 2024 → Nov 2026 expected | non-small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06819774 | Apr 2024 → Aug 2025 overdue | urticaria | Shandong New Time Pharmaceutical Co., LTD | Recruiting | No outcome recorded |
| Phase 3 | NCT03338764 | May → Dec 2023 | insomnia | Sequential Medicine Ltd | Withdrawn | No outcome recorded |
| Phase 3 | NCT04175834 | Feb 2020 → May 2022 | multiple sclerosis | Providence Health & Services | Completed | No outcome recorded |
| Phase 3 | NCT03331042 | Oct 2017 → Mar 2018 | insomnia | Sequential Medicine Ltd | Completed | No outcome recorded |
| Phase 3 | NCT02374567 | Jan 2015 → Jun 2017 | anxiety disorder, dementia, depressive disorder, schizophrenia +1 | Hannover Medical School | Terminated | No outcome recorded |
| Phase 3 | NCT01888497 | Jul → Dec 2013 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01495858 | Dec 2011 → Feb 2012 | — | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT01177852 | Oct 2011 → Apr 2012 | rhinitis | Ache Laboratorios Farmaceuticos S.A. | Withdrawn | No outcome recorded |
| Phase 3 | NCT01199497 | Aug 2011 → Aug 2012 | nasal cavity disorder | Ache Laboratorios Farmaceuticos S.A. | Withdrawn | No outcome recorded |
| Phase 3 | NCT01365052 | May → Jul 2011 | — | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT01100645 | Oct 2010 → Jan 2011 | insomnia | Azidus Brasil | Unknown | No outcome recorded |
| Phase 3 | NCT00814359 | May 2009 → Sep 2010 | head and neck cancer, mucositis | Juravinski Cancer Centre Foundation | Completed | No outcome recorded |
| Phase 415 trials | ||||||
| Phase 4 | NCT07542756 | May 2026 → Jan 2032 expected | insomnia | University of Pennsylvania | Recruiting | No outcome recorded |
| Phase 4 | NCT07542730 | May 2026 → Feb 2027 expected | anxiety | University of Rochester | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06819033 | Mar 2025 → Feb 2026 overdue | aphthous stomatitis | The University of Texas Health Science Center, Houston | Recruiting | No outcome recorded |
| Phase 4 | NCT06217367 | Dec 2023 → Jun 2024 | allergic rhinitis, dysautonomia-like disorder | Lakehead University | Unknown | No outcome recorded |
| Phase 4 | NCT05586477 | Nov 2022 → Jun 2023 | allergic rhinitis | Lakehead University | Completed | No outcome recorded |
| Phase 4 | NCT05219604 | Mar → Oct 2022 | — | Dent Neuroscience Research Center | Terminated | No outcome recorded |
| Phase 4 | NCT04255420 | Feb 2020 → May 2021 | headache disorder | Kendall Healthcare Group, Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT03490396 | May 2018 → Nov 2019 | chemotherapy-induced oral mucositis | Midatech Pharma US Inc. | Terminated | No outcome recorded |
| Phase 4 | NCT02463929 | Apr → Jun 2014 | — | Universitas Diponegoro | Completed | No outcome recorded |
| Phase 4 | NCT02062710 | Jan → Jun 2014 | — | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01967433 | Dec 2013 → Mar 2018 | — | University of Oklahoma | Completed | No outcome recorded |
| Phase 4 | NCT02578186 | Nov 2013 → Dec 2014 | insomnia | Procter and Gamble | Completed | No outcome recorded |
| Phase 4 | NCT00638443 | Mar 2008 → Mar 2010 | lumbar spinal stenosis | University of Rochester | Completed | No outcome recorded |
| Phase 4 | NCT00937924 | Feb 2008 → Jun 2012 | — | University of California, Irvine | Completed | No outcome recorded |
| Phase 4 | NCT00648973 | Nov 2006 → May 2007 | nasal cavity disorder | Johnson & Johnson Consumer and Personal Products Worldwide | Completed | No outcome recorded |
| Phase not applicable8 trials | ||||||
| — | NCT07285031 | Dec 2025 → Aug 2026 overdue | — | University of British Columbia | Recruiting | No outcome recorded |
| — | NCT05036174 | Sep 2021 → Apr 2022 | osteoarthritis, knee | Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology | Unknown | No outcome recorded |
| — | NCT04700007 | Jan → Dec 2021 | — | Aalborg University | Completed | No outcome recorded |
| — | NCT01556932 | Mar 2012 → May 2013 | — | Virginia Commonwealth University | Completed | No outcome recorded |
| — | NCT01321021 | Mar → Jul 2011 | — | University of Basel | Completed | No outcome recorded |
| — | NCT01204255 | Nov 2010 → Apr 2011 | — | Virginia Commonwealth University | Completed | No outcome recorded |
| — | NCT01067677 | Feb 2010 → Feb 2012 | — | Franklyn Cladis | Withdrawn | No outcome recorded |
| — | NCT00961792 | Mar 2004 → Sep 2026 expected | alcohol dependence | University of Chicago | Active not recruiting | No outcome recorded |
Also used as a comparator or background therapy in 176 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05013437 Background | Sep → Dec 2023 | plasma cell myeloma | Koen van Besien | Withdrawn | No outcome recorded |
| Phase 0 | NCT03688464 Comparator | Feb 2019 | atopic eczema | University of Nebraska | Withdrawn | No outcome recorded |
| Phase 131 trials | ||||||
| Phase 1 | NCT06070649 Comparator | Aug 2025 → Aug 2026 overdue | alcohol-related disorders | Yale University | Recruiting | No outcome recorded |
| Phase 1 | NCT05729555 Comparator | Apr → Oct 2023 | insomnia | Overseas Pharmaceuticals, Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05211336 Background | Apr 2022 → Jun 2024 overdue | diffuse large B-cell lymphoma of the central nervous system | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05302388 Background | Apr 2022 → Jan 2023 | — | Shanghai Institute Of Biological Products | Completed | No outcome recorded |
| Phase 1 | NCT04599634 Background | Dec 2021 → Mar 2024 | chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT04840615 Background | Jun → Dec 2021 | mesothelioma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT04681105 Background | Nov 2020 → Aug 2025 | B-cell acute lymphoblastic leukemia, CD4+/CD56+ hematodermic neoplasm, Hodgkins lymphoma, T-cell acute lymphoblastic leukemia +4 | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT04580121 Background | Nov 2020 → Aug 2023 | acute myeloid leukemia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT03805932 Background | Oct 2019 → Jul 2023 overdue | hairy cell leukemia | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03619954 Background | Jul 2018 → Jul 2019 | — | Anhui Provincial Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT03258593 Background | Jun 2018 → Aug 2022 | urinary bladder neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT03459612 Comparator | Mar → Jun 2018 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03448393 Background | Mar 2018 → Jul 2024 | B-cell non-Hodgkin lymphoma, acute lymphoblastic leukemia | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT03330028 Background | Oct 2017 → Apr 2023 | upper digestive tract disorder | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT02240407 Background | Oct 2017 → Aug 2021 | glycogen storage disease II | University of Florida | Completed | No outcome recorded |
| Phase 1 | NCT03324113 Background | Oct 2017 → Nov 2022 | cancer | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT03142165 Background | May → Nov 2017 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02648490 Background | Sep 2016 → Jun 2019 | cancer | Henlix, Inc | Completed | No outcome recorded |
| Phase 1 | NCT02867800 Background | Jul 2016 → Dec 2021 | graft versus host disease, sickle cell disease | Monica Bhatia | Completed | No outcome recorded |
| Phase 1 | NCT02797522 Background | Jun → Nov 2016 | hepatitis B virus infection | Arrowhead Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT02535416 Background | Sep 2015 → Aug 2016 | — | Arrowhead Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02363946 Background | Feb 2015 → Nov 2016 | alpha 1-antitrypsin deficiency | Arrowhead Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT02188719 Background | Dec 2014 → Jun 2019 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 1 | NCT02033707 Background | Apr 2014 → Feb 2019 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT01998971 Background | Feb 2014 → Jan 2019 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01712828 Background | Oct 2012 → Jan 2013 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01666678 Comparator | Jan → Feb 2012 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT01411124 Comparator | Jun → Oct 2011 | restless legs syndrome | XenoPort, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01289938 Comparator | Jul 2009 → Jun 2015 | — | Matthias Schwab | Terminated | No outcome recorded |
| Phase 1 | NCT00840853 Background | Apr 2009 → Apr 2016 overdue | B-cell acute lymphoblastic leukemia, B-cell chronic lymphocytic leukemia | Baylor College of Medicine | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01119222 Comparator | Jul → Oct 2008 | — | Pfizer | Completed | No outcome recorded |
| Phase 1/218 trials | ||||||
| Phase 1/2 | NCT07227597 Background | Jan 2026 → Nov 2030 expected | small cell lung carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06207305 Background | Jan 2024 → Jan 2028 expected | appendix adenocarcinoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05768919 Background | Mar 2023 → Feb 2026 overdue | glioblastoma | SignPath Pharma, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04432597 Background | Aug 2020 → Nov 2022 overdue | anal carcinoma, cervical cancer, oropharynx cancer, virus associated tumor | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04294459 Background | Jun 2020 → May 2022 | immune system disorder | Sanofi | Terminated | No outcome recorded |
| Phase 1/2 | NCT04224558 Background | Nov 2019 → Sep 2027 expected | Crohn disease | Cedars-Sinai Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03554473 Background | Sep 2018 → Jun 2022 | small cell lung carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT03383887 Comparator | Dec 2017 → Jan 2020 | obstructive sleep apnea syndrome | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT03056352 Background | Mar → Jul 2017 | — | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT02858310 Background | Jan 2017 → Jul 2025 | cervical intraepithelial neoplasia, human papilloma virus infection, in situ carcinoma, vulvar neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT02711826 Background | Sep 2016 → Aug 2023 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/2 | NCT02474199 Background | Jun 2016 → Dec 2019 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/2 | NCT02356159 Background | Sep 2015 → Dec 2024 | Hodgkins lymphoma, acute leukemia, myelodysplastic syndrome, non-Hodgkin lymphoma +1 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT02300727 Comparator | Feb 2015 → Oct 2018 | mucositis | Amy Beres | Terminated | No outcome recorded |
| Phase 1/2 | NCT01455389 Background | Feb 2014 → Oct 2016 | lung cancer | Genprex, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT00923910 Background | Feb 2008 → Oct 2013 | acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00226941 Background | Jun 2004 → Mar 2008 | rectal cancer | George Albert Fisher | Terminated | No outcome recorded |
| Phase 1/2 | NCT00078559 Background | Nov 2003 → Feb 2010 | kidney disorder | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 255 trials | ||||||
| Phase 2 | NCT07709000 Background | Aug 2026 → Nov 2033 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | Merck Sharp & Dohme LLC | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06356571 Background | Mar 2025 → Jan 2027 expected | plasma cell myeloma | Sanofi | Recruiting | No outcome recorded |
| Phase 2 | NCT05896228 Background | Feb 2024 → Mar 2029 expected | plasma cell myeloma | Benjamin T Diamond, MD | Recruiting | No outcome recorded |
| Phase 2 | NCT06043323 Background | Jan 2024 → Sep 2026 expected | follicular lymphoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06083571 Background | Jan 2024 → Dec 2025 | migraine disorder | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 2 | NCT05977998 Background | Sep 2023 → Oct 2028 expected | gastric adenocarcinoma, metastatic carcinoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05807048 Background | Jun 2023 → Nov 2025 | lung cancer | NYU Langone Health | Completed | No outcome recorded |
| Phase 2 | NCT05866510 Background | May 2023 → Apr 2024 | esophageal cancer | Peking University | Unknown | No outcome recorded |
| Phase 2 | NCT05704049 Background | Apr 2023 → Dec 2025 overdue | refractory plasma cell neoplasm | Sanofi | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05039619 Background | May 2022 → Jun 2028 expected | lupus nephritis | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 2 | NCT05285813 Background | May 2022 → May 2026 | acute myeloid leukemia, myelodysplastic syndrome | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT05298683 Background | May 2022 → Nov 2025 | impaired renal function disease, monoclonal paraproteinemia disease, plasma cell myeloma | Hellenic Society of Hematology | Unknown | No outcome recorded |
| Phase 2 | NCT04743661 Background | Apr 2022 → Mar 2026 overdue | ependymoma, medulloblastoma | Pediatric Brain Tumor Consortium | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04862221 Background | Feb 2022 → Aug 2026 overdue | acute liver failure, hepatic encephalopathy, immune dysregulation, autoimmunity, and autoinflammation | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Recruiting | No outcome recorded |
| Phase 2 | NCT04918147 Background | Oct 2021 → Jan 2024 | immunoglobulin G4-related sclerosing disease | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 2 | NCT04660799 Background | Feb 2021 → May 2022 | diffuse large B-cell lymphoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT04109885 Comparator | Sep 2020 → Jan 2024 | headache disorder | Christian Fromm, MD | Terminated | No outcome recorded |
| Phase 2 | NCT03456817 Background | Jul 2020 → May 2025 | graft versus host disease | AHS Cancer Control Alberta | Terminated | No outcome recorded |
| Phase 2 | NCT04396327 Background | May → Jun 2020 overdue | insomnia | Sequential Medicine Ltd | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04189588 Comparator | Mar → Nov 2020 | — | TerSera Therapeutics LLC | Completed | No outcome recorded |
| Phase 2 | NCT04268498 Background | Feb 2020 → Feb 2027 expected | plasma cell myeloma | University of Miami | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04165096 Background | Jan 2020 → Apr 2025 | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT03913559 Background | May 2019 → Sep 2025 | acute lymphoblastic leukemia | St. Jude Children's Research Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT04308837 Background | Dec 2018 → Aug 2025 | gastric cancer | Icahn School of Medicine at Mount Sinai | Unknown | No outcome recorded |
| Phase 2 | NCT03107182 Background | Jun 2017 → Sep 2024 | head and neck squamous cell carcinoma, human papillomavirus-related squamous cell carcinoma | University of Chicago | Completed | No outcome recorded |
| Phase 2 | NCT02999633 Background | Mar → Nov 2017 | T lymphoblastic leukemia/lymphoma, precursor T-cell acute lymphoblastic leukemia | Sanofi | Terminated | No outcome recorded |
| Phase 2 | NCT02738008 Background | Mar → Dec 2016 | hepatitis B virus infection | Arrowhead Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT02495077 Background | Nov 2015 → Jul 2021 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT02604212 Background | Nov 2015 → Dec 2016 | hepatitis B virus infection | Arrowhead Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT02604199 Background | Sep 2015 → Jan 2017 | chronic hepatitis B virus infection | Arrowhead Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT02452528 Background | Aug 2015 → Dec 2016 | chronic hepatitis B virus infection | Arrowhead Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT02260934 Background | Jul 2015 → Mar 2018 | lupus nephritis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT02061293 Comparator | Jun 2014 → Jul 2021 | alcohol dependence | NYU Langone Health | Completed | No outcome recorded |
| Phase 2 | NCT02029638 Background | Jan 2014 → Sep 2017 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 2 | NCT01985126 Background | Sep 2013 → Jan 2015 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT01392183 Background | Oct 2012 → Sep 2019 | kidney cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01332630 Background | Aug 2011 → Apr 2017 | breast cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01086540 Background | Jun 2011 → Jun 2018 | pulmonary arterial hypertension | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT01293968 Background | Nov 2010 → Jan 2011 | aphthous stomatitis | Qazvin University Of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01059786 Background | Jul 2010 → Dec 2022 overdue | hairy cell leukemia | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01017731 Background | Nov 2009 → Apr 2010 | cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00887640 Background | Jul 2009 → Aug 2012 | prostate cancer | Duke University | Terminated | No outcome recorded |
| Phase 2 | NCT00899847 Background | May 2009 → Apr 2014 | plasma cell myeloma | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT00866788 Background | Mar 2009 → Jan 2010 | chronic idiopathic urticaria | Genentech, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00771875 Background | Sep 2008 → Dec 2012 | transplant rejection | University of Cincinnati | Completed | No outcome recorded |
| Phase 2 | NCT01332318 Comparator | Apr → Nov 2007 | restless legs syndrome | XenoPort, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00346151 Background | Dec 2006 → Feb 2010 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 2 | NCT00482053 Background | Oct 2006 → May 2010 | diffuse large B-cell lymphoma | Stanford University | Terminated | No outcome recorded |
| Phase 2 | NCT00324467 Comparator | Aug 2006 → Dec 2021 | diffuse large B-cell lymphoma | British Columbia Cancer Agency | Unknown | No outcome recorded |
| Phase 2 | NCT00186628 Background | Jun 2005 → Nov 2010 | mantle cell lymphoma, mast cell leukemia | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT00490009 Background | Sep 2004 → Apr 2010 | lymphoma | Susan Knox | Completed | No outcome recorded |
| Phase 2 | NCT00076752 Background | Jan 2004 → Oct 2013 | systemic lupus erythematosus | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00030992 Background | Feb 2002 → Jan 2009 | renal cell carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00515073 Background | Apr 2001 → May 2013 | endometrial cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00185692 Background | Aug 2000 → Dec 2010 | B-cell chronic lymphocytic leukemia, Hodgkins lymphoma, cancer, graft versus host disease +1 | Stanford University | Completed | No outcome recorded |
| Phase 2/35 trials | ||||||
| Phase 2/3 | NCT07570173 Background | May 2026 → Oct 2033 expected | B-cell acute lymphoblastic leukemia | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04862585 Comparator | Oct 2021 → Jun 2024 | breast carcinoma in situ, female breast carcinoma | Ohio State University Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2/3 | NCT01604785 Comparator | Nov 2012 → Aug 2016 | migraine disorder | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 2/3 | NCT01837446 Comparator | Jul 2011 → Jul 2012 | stomatitis | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT00137969 Background | May 2005 → Aug 2008 | systemic lupus erythematosus | Genentech, Inc. | Completed | No outcome recorded |
| Phase 329 trials | ||||||
| Phase 3 | NCT07472413 Comparator | Sep 2026 → Jul 2028 expected | multiple sclerosis | University of Miami | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05673590 Background | May 2023 → Jun 2025 | non-small cell lung carcinoma | Beijing Biostar Pharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT05627557 Background | Mar 2023 → Sep 2025 overdue | idiopathic nephrotic syndrome | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05648058 Comparator | Dec 2022 → Oct 2023 | — | Ministry Of Health / Nineveh Health Directorate | Unknown | No outcome recorded |
| Phase 3 | NCT05405166 Background | Jun 2022 → Nov 2024 overdue | plasma cell myeloma | Sanofi | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05115136 Comparator | May 2022 → Jan 2023 | urticaria | State University of New York - Upstate Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT05232825 Comparator | May 2022 → Mar 2023 | primary progressive multiple sclerosis | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT05244460 Background | Dec 2021 → Jan 2023 | cannabinoid hyperemesis syndrome | Mercy Health Ohio | Unknown | No outcome recorded |
| Phase 3 | NCT04963296 Background | Oct 2021 → Sep 2025 overdue | systemic lupus erythematosus | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04629248 Background | Jun 2021 → Dec 2025 overdue | idiopathic membranous glomerulonephritis | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04548999 Background | Dec 2020 → Jun 2025 overdue | primary progressive multiple sclerosis | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04221477 Background | Aug 2020 → Aug 2024 overdue | lupus nephritis | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04270409 Background | Jun 2020 → Oct 2030 expected | plasma cell myeloma | Sanofi | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04237090 Comparator | Feb → Aug 2020 | breast cancer, cervical cancer, endometrial cancer, esophageal cancer +3 | Ciusss de L'Est de l'Île de Montréal | Completed | No outcome recorded |
| Phase 3 | NCT03368664 Background | Oct 2017 → May 2021 | multiple sclerosis | Genzyme, a Sanofi Company | Terminated | No outcome recorded |
| Phase 3 | NCT03220958 Background | Aug 2017 → Apr 2020 | traumatic encephalopathy | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT02935699 Comparator | Mar 2017 → Apr 2018 | urticaria | JDP Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02735343 Background | Aug 2016 → May 2017 | headache disorder | Mike O'Callaghan Military Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT03081416 Comparator | May → Sep 2016 | headache disorder | Brooke Army Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT02688985 Background | Apr 2016 → Apr 2023 | primary progressive multiple sclerosis | Genentech, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02229539 Comparator | Nov 2014 → May 2016 | mucositis | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 3 | NCT02023164 Comparator | Jul 2013 → Dec 2014 | urticaria | JDP Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01264939 Background | Feb 2011 → Nov 2012 | chronic idiopathic urticaria | Genentech, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01280591 Comparator | Oct 2010 → Jan 2011 | — | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT01858090 Comparator | Jan → Oct 2009 | — | Baskent University | Completed | No outcome recorded |
| Phase 3 | NCT00719472 Background | Jul 2008 → May 2011 | non-Hodgkin lymphoma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00682734 Background | Apr 2008 → Mar 2010 | migraine disorder | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT00381810 Background | Jun 2006 → Jul 2008 | systemic lupus erythematosus | Genentech, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00282347 Background | Jan 2006 → Jan 2009 | lupus nephritis | Genentech, Inc. | Completed | No outcome recorded |
| Phase 417 trials | ||||||
| Phase 4 | NCT06019728 Background | Nov 2023 → Oct 2024 | Fabry disease | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT06310642 Background | May 2021 → Mar 2023 | acute mountain sickness | CHRISTUS Health | Completed | No outcome recorded |
| Phase 4 | NCT03968939 Comparator | Oct 2019 → Mar 2022 | — | James A. Keeney | Completed | No outcome recorded |
| Phase 4 | NCT03185130 Background | May 2017 → May 2019 | headache disorder | University Medical Center of Southern Nevada | Completed | No outcome recorded |
| Phase 4 | NCT02657031 Comparator | Mar 2016 → Mar 2017 | headache disorder | University Medical Center of Southern Nevada | Completed | No outcome recorded |
| Phase 4 | NCT02441894 Background | Apr 2015 → Feb 2016 | prostate cancer | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT02389829 Comparator | Mar 2015 → Jun 2016 | migraine disorder | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02339155 Background | Feb 2015 → Jan 2017 | bacterial infectious disease | Emergent BioSolutions | Completed | No outcome recorded |
| Phase 4 | NCT02972502 Background | Feb 2014 → Apr 2017 | migraine disorder | OhioHealth | Terminated | No outcome recorded |
| Phase 4 | NCT01985789 Comparator | Nov 2013 → May 2014 | asthma | Don Cockcroft | Completed | No outcome recorded |
| Phase 4 | NCT02098499 Comparator | Jun 2013 → Feb 2015 | migraine disorder | United States Naval Medical Center, Portsmouth | Withdrawn | No outcome recorded |
| Phase 4 | NCT01825941 Comparator | Apr 2013 → Dec 2014 | migraine disorder | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01382940 Background | Jul 2011 → Jan 2013 | rheumatoid arthritis | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT01158820 Comparator | Jun 2010 → May 2012 | — | University of Pennsylvania | Completed | No outcome recorded |
| Phase 4 | NCT01011673 Comparator | Nov 2009 → Sep 2012 | headache disorder | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01118273 Comparator | Jan → Feb 2008 | — | Bayer | Completed | No outcome recorded |
| Phase 4 | NCT00475306 Comparator | May 2007 → Feb 2008 | extrapyramidal and movement disease | Montefiore Medical Center | Completed | No outcome recorded |
| Phase not applicable18 trials | ||||||
| — | NCT06345261 Comparator | Apr 2024 → Apr 2025 | — | Cairo University | Unknown | No outcome recorded |
| — | NCT06182098 Background | Jun 2023 → Jun 2025 | migraine disorder | Dayton Children's Hospital | Unknown | No outcome recorded |
| — | NCT05676216 Comparator | Jan 2023 → Dec 2024 | peripheral vertigo | National Taiwan University Hospital | Unknown | No outcome recorded |
| — | NCT04237428 Background | May → Jun 2019 | non-Hodgkin lymphoma | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Unknown | No outcome recorded |
| — | NCT02681211 Comparator | Feb 2016 → Nov 2024 | migraine disorder | University of Louisville | Unknown | No outcome recorded |
| — | NCT02655354 Background | Oct 2015 → Nov 2019 | alcohol-related disorders, brain injury, cognitive impairment with or without cerebellar ataxia, depressive disorder +1 | University of Washington | Completed | No outcome recorded |
| — | NCT01769586 Comparator | Feb 2013 → Jun 2015 | — | VA Connecticut Healthcare System | Completed | No outcome recorded |
| — | NCT02179814 Comparator | Feb 2012 → May 2019 | bulimia nervosa | University of Bern | Suspended | No outcome recorded |
| — | NCT02295280 Comparator | Jan 2012 → Nov 2014 | headache disorder | St. Louis University | Completed | No outcome recorded |
| — | NCT01669967 Comparator | Sep 2011 → Dec 2015 | neuropathy, painful | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| — | NCT01451762 Comparator | Sep 2011 → Sep 2012 | — | Northwestern University | Completed | No outcome recorded |
| — | NCT03435692 Background | Jul 2011 → Jul 2014 | — | Seattle Children's Hospital | Terminated | No outcome recorded |
| — | NCT01406860 Comparator | Jul 2011 → Jul 2012 | headache disorder | University of Iowa | Terminated | No outcome recorded |
| — | NCT00991809 Comparator | Feb 2009 → May 2010 | — | Johns Hopkins University | Completed | No outcome recorded |
| — | NCT00573599 Background | Feb → May 2007 | migraine disorder | United States Naval Medical Center, Portsmouth | Withdrawn | No outcome recorded |
| — | NCT00641797 Comparator | Nov 2006 → Dec 2010 | benign paroxysmal positional vertigo | Lehigh Valley Hospital | Completed | No outcome recorded |
| — | NCT00137202 Comparator | Jun 2005 → May 2006 | — | United States Army Institute of Surgical Research | Completed | No outcome recorded |
| — | NCT00000875 Background | ? → Apr 2003 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04456439 Background | — | COVID-19–associated multisystem inflammatory syndrome in children | Mesoblast, Ltd. | No longer available | No outcome recorded |
Evidence & citations 17 cited values
Every value below carries the sentence it was read from. 235 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Diphenhydramine | “Recommended rescue medications include tocilizumab for treatment of cytokine release syndrome (CRS); dexamethasone, acetaminophen, and diphenhydramine for CRS/infusion-related...” NCT07227597 ↗215“Before the use of utidelone, all patients will accept pretreatment: diphenhydramine 40 mg by intramuscular injection or oral administration, and dexamethasone10 mg and...” NCT05866510 ↗ “Premedication with oral or IV antihistaminic drug (i.e., diphenhydramine 50 mg or an equivalent dose of an alternative) will be administered prior to each ocrelizumab infusion.” NCT04548999 ↗ “The antihistamine used should in general be an H1\>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg.” NCT02604212 ↗ “Participants received one tablet of Naproxen Sodium 220 mg / Diphenhydramine hydrochloride (DPH) 25 mg and one tablet of Naproxen Sodium 220 mg, single dose, orally.” NCT01495858 ↗ “An analgesic/antipyretic (eg, acetaminophen) and an antihistamine (eg, diphenhydramine) were administered 30 minutes before each infusion of rituximab.” NCT00719472 ↗ “Antihistamine (e.g., diphenhydramine) or equivalent medications per institutional standard may be administered at the discretion of the investigator.” NCT03258593 ↗ “Subjects are premedicated with glucocorticoids, acetaminophen 650 mg by mouth, and diphenhydramine 25- 50 mg by mouth prior to each dose.” NCT00346151 ↗ “An antihistamine (e.g., IV diphenhydramine \[1 mg/kg, 50 mg maximum\] or equivalent) will be given as premedication for 131I-omburtamab” NCT04743661 ↗ “3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam.” NCT03331042 ↗ “Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.” NCT01118273 ↗ “reference 1 (R1): Ibuprofen Tablets (Motrin IB®)reference 2 (R2): Diphenhydramine Hydrochloride Tablets (Benadryl®)” NCT05729555 ↗ “powder included dexamethasone, diphenhydramine, tetracycline, metronidazole, nystatin, zinc oxide, and karaya gum” NCT02142543 ↗ “one night of pseudoephedrine 120 mg plus diphenhydramine 50 mg (DAW1033D) to placebo administered prior to sleep.” PMID 33491327 ↗ Jan 2021 “Viscous Lidocaine, Diphenhydramine, and Aluminum-magnesium Hydroxide/Simethicone Antacid Suspension Mouthwash” NCT03490396 ↗ “Benadryl (Diphenhydramine) is often used in addition to these medications in an effort to improve sedation.” NCT00240123 ↗ “Participants will receive an antihistamine, such as diphenhydramine, prior to ocrelizumab infusion.” NCT02688985 ↗ “would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg.” NCT02738008 ↗ “would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg.” NCT02604199 ↗ “3-drug combination product containing 50 mg diphenhydramine, 5 mg zolpidem and 0.5 mg lorazepam” NCT02671760 ↗ “3-drug combination product containing 50 mg diphenhydramine, 5 mg zolpidem and 0.5 mg lorazepam” NCT04396327 ↗ “fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).” NCT01199497 ↗ “SM-1 is a combination drug product containing diphenhydramine, zolpidem and lorazepam.” NCT03338764 ↗ “Pretreatment: diphenhydramine 40 mg by intramuscular injection or oral administration” NCT05673590 ↗ “Intravenous prochlorperazine 10 mg plus diphenhydramine 50 mg will be administered.” NCT04255420 ↗ “magic mouthwash (diphenhydramine, dexamethasone and nystatin) plus sucralfate” NCT00814359 ↗ “ATG premeds include methylprednisolone, diphenhydramine, and an antipyretic.” NCT03456817 ↗ “Premedication/Precautions: Dexamethasone 4mg IV, Diphenhydramine 25 mg IV” NCT05768919 ↗ “DPH (Diphenhydramine hydrochloride) 25mg tablets orally, single dose” NCT01280591 ↗ “Diphenhydramine 25 to 50 mg (or equivalent) orally or intravenously” NCT05807048 ↗ “metoclopramide 20mg IVSS + diphenhydramine 25mg IVSS” NCT01011673 ↗ “Antihistamines: diphenhydramine, chlorpheniramine” NCT02033707 ↗ “Safety Trial of Naproxen Sodium/ Diphenhydramine” NCT01365052 ↗ “diphenhydramine 0.5-1mg/kg, no more than 50mg.” NCT04237428 ↗ “Ketorolac, Diphenhydramine and Metoclopramide” NCT01604785 ↗ “Compazine 10mg with diphenhydramine 25 mg IV” NCT02735343 ↗ “diphenhydramine 50 mg by mouth (PO)” NCT02797522 ↗ “diphenhydramine 50mg po.” NCT03619954 ↗ “Drug: Diphenhydramine” NCT02657031 ↗ “Drug: Diphenhydramine” NCT01017731 ↗ “diphenhydramine” NCT00771875 ↗ |
| Known as | Benadryl | “reference 1 (R1): Ibuprofen Tablets (Motrin IB®)reference 2 (R2): Diphenhydramine Hydrochloride Tablets (Benadryl®)” NCT05729555 ↗13“Benadryl 25 to 50 mg by vein approximately 30 minutes before the start of each dose of temsirolimus.” NCT01392183 ↗ “The standard mouth rinse contains 40% Benadryl, 40% Maalox, and 20% of 1% Viscous Lidocaine.” NCT02300727 ↗ “diphenhydramine, a first-generation antihistamine sold commercially as Benadryl®.” NCT05586477 ↗ “Oral Diphenhydramine (Benadryl), 25 mg” NCT03968939 ↗ “diphenhydramine (Benadryl)” NCT03456817 ↗ “Diphenhydramine (Benadryl)” NCT00137202 ↗ |
| Known as | Benadryl demand | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01158820 ↗ |
| Known as | DHP HCL | “naproxen sodium/diphenhydramine hydrochloride (DHP HCL) 220/25 mg soft capsules” NCT03424135 ↗ |
| Known as | Diphenhydramin | “Diphenhydramin cream 1% (Restamine®) will be applied on a 3x3 cm squared predetermined area on the volar forearm for 24 hours.” NCT04700007 ↗ |
| Known as | Diphenhydramine citrate | “Ibuprofen 400 mg / Diphenhydramine citrate 76 mg” NCT01118273 ↗ |
| Known as | Diphenhydramine HCl | “A single liquid dose of diphenhydramine HCl (12.5 mg /5 mL) followed by water, according to an age-weight dosing schedule” NCT00762749 ↗4“Diphenhydramine HCl 0.5-1 mg/kg (maximum dose 50 mg) will be administered PO or IV as premedication prior to infusions.” NCT05627557 ↗ “Diphenhydramine HCl 50 mg will be administered as pre-medication prior to infusions.” NCT05039619 ↗ “2 x Diphenhydramine HCl 25 mg under fasting conditions” NCT01666678 ↗ |
| Known as | Diphenhydramine Hydrochloride | “To evaluate the relative bioavailability of Naproxen Sodium 220 mg and diphenhydramine hydrochloride (DPH HCL) 25 mg soft capsules (Test) versus Naproxen Sodium 220 mg and...” NCT03396250 ↗10“Diphenhydramine hydrochloride (herein referred to as diphenhydramine) is an antihistamine of the ethanolamine classes with known sleep-inducing properties and is approved by...” NCT02578186 ↗ “The primary purpose of the present study was to examine whether diphenhydramine hydrochloride (DPH), a first-generation antihistamine, affects the sweating, core temperature,...” PMID 39140777 ↗ Jul 2024 “The subjects received 1 ml of the injection of Diphenhydramine Hydrochloride (for deep intramuscular injection) and 1 ml of the injection of Simulated Cetirizine Hydrochloride...” NCT06819774 ↗ “Participants received one tablet of Naproxen Sodium 220 mg / Diphenhydramine hydrochloride (DPH) 25 mg and one tablet of Naproxen Sodium 220 mg, single dose, orally.” NCT01495858 ↗ “50 mg diphenhydramine hydrochloride or equivalent dose of alternate antihistamine administered orally 30 to 60 minutes prior to the start of each study drug infusion” NCT01382940 ↗ “Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.” NCT01118273 ↗ “reference 1 (R1): Ibuprofen Tablets (Motrin IB®)reference 2 (R2): Diphenhydramine Hydrochloride Tablets (Benadryl®)” NCT05729555 ↗ “Drug: Diphenhydramine Hydrochloride” NCT05627557 ↗ |
| Known as | Diphenhydramine hydrochloride (HCl) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00226941 ↗ |
| Known as | Diphenydramine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00185692 ↗ |
| Known as | DPH | “The primary purpose of the present study was to examine whether diphenhydramine hydrochloride (DPH), a first-generation antihistamine, affects the sweating, core temperature,...” PMID 39140777 ↗ Jul 20244“The purpose of this trial is to see how safe the combination of naproxen sodium 440 mg and diphenhydramine hydrochloride (DPH) 50 mg (the investigational product) is compared to placebo” NCT01365052 ↗ “Participants received one tablet of Naproxen Sodium 220 mg / Diphenhydramine hydrochloride (DPH) 25 mg and one tablet of Naproxen Sodium 220 mg, single dose, orally.” NCT01495858 ↗ “Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.” NCT01118273 ↗ “novel combination naproxen sodium (NS) and diphenhydramine (DPH)” PMID 25996289 ↗ May 2015 |
| Known as | DPH HCl | “To evaluate the relative bioavailability of Naproxen Sodium 220 mg and diphenhydramine hydrochloride (DPH HCL) 25 mg soft capsules (Test) versus Naproxen Sodium 220 mg and...” NCT03396250 ↗ |
| Known as | Restamine | “Diphenhydramin cream 1% (Restamine®) will be applied on a 3x3 cm squared predetermined area on the volar forearm for 24 hours.” NCT04700007 ↗ |
| Known as | Sominex | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01100645 ↗ |
| Action | Inhibit | “the histamine H1 receptor antagonist diphenhydramine” NCT01321021 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Efficacy and Safety of the Herbal Medicine Sominex ® (Passiflora Incarnata L., Valeriana Officinalis L. and Crataegus Oxyacantha L.), Manufactured by the Laboratory EMS S / A...” NCT01100645 ↗ |
| Route | Intravenous | “50 mg intravenously 30-60 minutes prior to Ixabepilone (BMS-247550)” NCT00030992 ↗ |